Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321964 | 0.90 | GRM2 (0.60) | GRM2 | |
| SCHEMBL10321272 | 0.88 | GRM2 (0.72) | GRM2 | |
| SCHEMBL10321770 | 0.85 | GRM2 (0.56) | GRM2 | |
| SCHEMBL10320966 | 0.84 | GRM2 (0.74) | GRM2 | |
| SCHEMBL10321454 | 0.81 | GRM2 (0.53) | GRM2 | |
| SCHEMBL7861343 | 0.75 | GRM2 (0.55) | GRM2 | |
| SCHEMBL753387 | 0.75 | GRM2 (0.55) | GRM2 | |
| SCHEMBL739767 | 0.74 | GRM2 (1.00) | GRM2 | |
| SCHEMBL741150 | 0.73 | GRM2 (0.57) | GRM2 | |
| SCHEMBL10321605 | 0.73 | GRM2 (0.50) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946205-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | claimed |
| EP-2430031-B1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20120184527-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | claimed |
| CN-102439015-A | 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-8946205-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2430031-B1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120184527-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| CN-102439015-A | 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184527-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.